Ironwood Pharmaceuticals (IRWD) reported $296M in revenue for fiscal 2025, −15.7% year on year. That ranks #2487 by revenue among 2853 SEC filers and #250 in Healthcare. Net income was $24.0M, a net margin of 8.1%. Revenue has grown 11.3% a year on average since 2011 ($65.9M then). The fiscal 2025 balance sheet shows $397M in total assets, $215M in cash and $199M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $296M | −15.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $98.5M | +5.8% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $24.0M | +2,629.5% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $127M | +22.7% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $34,000 | −76.1% | FY20252025-12-31 |
| Total assetsAssets | $397M | +13.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$262M | +$39.5M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $215M | +143.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $199M | −50.0% | FY20242024-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $107M | $40.8M | Open → |
| Q2 20262026-06-30 | $113M | $51.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ironwood Pharmaceuticals Inc
- Ticker
- IRWD
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001446847
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| BilliontooneBLLN | $305M | $7.5M |
| Skinhealth SystemsSKIN | $301M | −$9.5M |
| EvolusEOLS | $297M | −$51.6M |
| Ironwood PharmaceuticalsIRWD | $296M | $24.0M |
| Rigel PharmaceuticalsRIGL | $294M | $367M |
| Xeris BiopharmaXERS | $292M | $554,000 |
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ironwood Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/ironwood-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ironwood Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ironwood-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-ironwood-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Ironwood Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ironwood-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-020489 · February 26, 2026
{{cite web |title=Ironwood Pharmaceuticals — Key figures — 10-K (0001104659-26-020489) |url=https://www.sec.gov/Archives/edgar/data/1446847/000110465926020489/irwd-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.